A genuinely multi-dimensional relaxation scheme for hyperbolic conservation laws

A novel genuinely multi-dimensional relaxation scheme is proposed. Based on a new discrete velocity Boltzmann equation, which is an improvement over previously introduced relaxation systems in terms of isotropic coverage of the multi-dimensional domain by the foot of the characteristic, a finite volume method is developed in which the fluxes at the cell interfaces are evaluated in a genuinely multi-dimensional way, in contrast to the traditional dimension-by-dimension treatment. This algorithm is tested on some bench-mark test problems for hyperbolic conservation laws

Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation: Report of an FDA Public Workshop

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138394/1/psp412204.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/138394/2/psp412204_am.pd

Comment on “Structural Determinants of Drug Partitioning in Surrogates of Phosphatidylcholine Bilayer Strata”

This article gives comment to a previous article published in 'Molecular Pharmaceuticals' titled, "Structural Determinants of Drug Partitioning in Surrogates of Phosphatidylcholine Bilayer Strata.

Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group

The critical importance of membrane-bound transporters in pharmacotherapy is widely recognized, but little is known about drug transporter activity in children. In this white paper, the Pediatric Transporter Working Group presents a systematic review of the ontogeny of clinically relevant membrane transporters (e.g., SLC, ABC superfamilies) in intestine, liver, and kidney. Different developmental patterns for individual transporters emerge, but much remains unknown. Recommendations to increase our understanding of membrane transporters in pediatric pharmacotherapy are presented

Towards third generation matrix metalloproteinase inhibitors for cancer therapy

The failure of matrix metalloproteinase (MMP) inhibitor drug clinical trials in cancer was partly due to the inadvertent inhibition of MMP antitargets that counterbalanced the benefits of MMP target inhibition. We explore how MMP inhibitor drugs might be developed to achieve potent selectivity for validated MMP targets yet therapeutically spare MMP antitargets that are critical in host protection